LeMaitre Vascular (NASDAQ:LMAT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01, Zacks reports. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%. LeMaitre Vascular updated its FY 2026 guidance to 2.810-3.010 EPS and its Q1 2026 guidance to 0.640-0.690 EPS.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q4 2025 delivered strong operating performance with 16% sales growth, a 71.7% gross margin, operating income up 47% and Q4 EPS of $0.68 (+39%); FY2025 organic revenue grew 14% and free cash flow was $74.5M with $359M in cash and securities.
• Management guided 2026 to $280M revenue (organic +12%), a 72.1% gross margin, adjusted operating income of $77.8M (+21%) and EPS of $2.91 (+22% adjusted), signaling continued operating leverage.
• Commercial momentum from new products and international expansion — Autograft now approved in 52 countries with an expected ~<$10M> in international autograft sales for 2026 (driving ~$6M of growth), Artegraft outperformed in 2025 (~$4M) and management sees a larger TAM (now suggesting ~ $30M) with further RFA/RestoreFlow geographic rollouts planned.
• Shareholder returns increased — board approved a new $100M share repurchase program and raised the Q1 2026 dividend 25% to $0.25, the 15th consecutive annual raise.
• Operational headwinds and risks — transferring RestoreFlow manufacturing to Burlington and consolidating the Chicago RFA facility will raise 2026 CapEx to ~ $11M and may pressure near-term margins, and a January 2026 cyber incident is under review (company says impact is reflected in guidance but risk remains).

LeMaitre Vascular Stock Up 0.7%

LeMaitre Vascular stock traded up $0.63 during midday trading on Wednesday, reaching $91.38. The stock had a trading volume of 198,933 shares, compared to its average volume of 145,201. The company has a fifty day moving average price of $85.86 and a two-hundred day moving average price of $88.09. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $105.55. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $2.07 billion, a P/E ratio of 39.39, a PEG ratio of 2.03 and a beta of 0.72.

Analyst Upgrades and Downgrades

A number of research firms have commented on LMAT. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Wells Fargo & Company reduced their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Cantor Fitzgerald restated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Barrington Research reiterated an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Friday, February 20th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Three analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Hold” and an average target price of $100.20.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the business. Illinois Municipal Retirement Fund grew its stake in shares of LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after buying an additional 123 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares during the last quarter. Federated Hermes Inc. boosted its holdings in LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after acquiring an additional 155 shares during the period. Equitable Holdings Inc. grew its position in LeMaitre Vascular by 1.4% during the 4th quarter. Equitable Holdings Inc. now owns 14,469 shares of the medical instruments supplier’s stock worth $1,173,000 after acquiring an additional 205 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in LeMaitre Vascular by 1.7% in the 2nd quarter. California State Teachers Retirement System now owns 18,721 shares of the medical instruments supplier’s stock worth $1,555,000 after purchasing an additional 316 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.